EGFR molecular testing in African-American non-small cell lung cancer patients - A review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Substantial discrepancy in the literature has recently emerged regarding epidermal growth factor receptor (EGFR) mutational frequency in African American (AA) NSCLC. The first wave of tissue profiling studies, including by our group in 2009, consistently observed a significantly lower frequency of EGFR mutation in AA vs. White NSCLC, whereas three recent reports appear to directly contradict these findings. Reasons for this discrepancy are unclear, but one plausible explanation arises from Simpson's paradox, the consequence of aggregating heterogeneous study cohorts (in this case, the proportion of never-smokers in the study cohort). Our review of all prior studies (combined total 386 AA NSCLC cases) underscores the wide variation in the proportion of AA never-smokers among various studies (13-57%), calling inter-study comparisons into question. In parallel, we assessed objective response by RECIST to EGFR targeted therapy for AA NSCLC in the community setting, prior to the advent of routine EGFR testing. We observed a trend toward reduced response for community-based treatment of unselected AA NSCLC (5%; 3/57) as compared to overall response rates of 10% reported by large North American trials of primarily White NSCLC patients, but this was not significant (P=0.223).

Original languageEnglish (US)
Pages (from-to)251-255
Number of pages5
JournalTranslational Lung Cancer Research
Volume2
Issue number3
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
African Americans
Cohort Studies
Mutation
Therapeutics

Keywords

  • African-American
  • Epidermal growth factor receptor (EGFR)
  • Non-small cell lung cancer
  • Simpson's paradox

ASJC Scopus subject areas

  • Oncology

Cite this

EGFR molecular testing in African-American non-small cell lung cancer patients - A review of discrepant data. / Clifford, Bradley T.; Fu, Pingfu; Pennell, Nathan A.; Halmos, Balazs; Leidner, Rom S.

In: Translational Lung Cancer Research, Vol. 2, No. 3, 2013, p. 251-255.

Research output: Contribution to journalReview article

Clifford, Bradley T. ; Fu, Pingfu ; Pennell, Nathan A. ; Halmos, Balazs ; Leidner, Rom S. / EGFR molecular testing in African-American non-small cell lung cancer patients - A review of discrepant data. In: Translational Lung Cancer Research. 2013 ; Vol. 2, No. 3. pp. 251-255.
@article{2e8b63627d10412f9badde670c676b77,
title = "EGFR molecular testing in African-American non-small cell lung cancer patients - A review of discrepant data",
abstract = "Substantial discrepancy in the literature has recently emerged regarding epidermal growth factor receptor (EGFR) mutational frequency in African American (AA) NSCLC. The first wave of tissue profiling studies, including by our group in 2009, consistently observed a significantly lower frequency of EGFR mutation in AA vs. White NSCLC, whereas three recent reports appear to directly contradict these findings. Reasons for this discrepancy are unclear, but one plausible explanation arises from Simpson's paradox, the consequence of aggregating heterogeneous study cohorts (in this case, the proportion of never-smokers in the study cohort). Our review of all prior studies (combined total 386 AA NSCLC cases) underscores the wide variation in the proportion of AA never-smokers among various studies (13-57{\%}), calling inter-study comparisons into question. In parallel, we assessed objective response by RECIST to EGFR targeted therapy for AA NSCLC in the community setting, prior to the advent of routine EGFR testing. We observed a trend toward reduced response for community-based treatment of unselected AA NSCLC (5{\%}; 3/57) as compared to overall response rates of 10{\%} reported by large North American trials of primarily White NSCLC patients, but this was not significant (P=0.223).",
keywords = "African-American, Epidermal growth factor receptor (EGFR), Non-small cell lung cancer, Simpson's paradox",
author = "Clifford, {Bradley T.} and Pingfu Fu and Pennell, {Nathan A.} and Balazs Halmos and Leidner, {Rom S.}",
year = "2013",
doi = "10.3978/j.issn.2218-6751.2013.01.04",
language = "English (US)",
volume = "2",
pages = "251--255",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "3",

}

TY - JOUR

T1 - EGFR molecular testing in African-American non-small cell lung cancer patients - A review of discrepant data

AU - Clifford, Bradley T.

AU - Fu, Pingfu

AU - Pennell, Nathan A.

AU - Halmos, Balazs

AU - Leidner, Rom S.

PY - 2013

Y1 - 2013

N2 - Substantial discrepancy in the literature has recently emerged regarding epidermal growth factor receptor (EGFR) mutational frequency in African American (AA) NSCLC. The first wave of tissue profiling studies, including by our group in 2009, consistently observed a significantly lower frequency of EGFR mutation in AA vs. White NSCLC, whereas three recent reports appear to directly contradict these findings. Reasons for this discrepancy are unclear, but one plausible explanation arises from Simpson's paradox, the consequence of aggregating heterogeneous study cohorts (in this case, the proportion of never-smokers in the study cohort). Our review of all prior studies (combined total 386 AA NSCLC cases) underscores the wide variation in the proportion of AA never-smokers among various studies (13-57%), calling inter-study comparisons into question. In parallel, we assessed objective response by RECIST to EGFR targeted therapy for AA NSCLC in the community setting, prior to the advent of routine EGFR testing. We observed a trend toward reduced response for community-based treatment of unselected AA NSCLC (5%; 3/57) as compared to overall response rates of 10% reported by large North American trials of primarily White NSCLC patients, but this was not significant (P=0.223).

AB - Substantial discrepancy in the literature has recently emerged regarding epidermal growth factor receptor (EGFR) mutational frequency in African American (AA) NSCLC. The first wave of tissue profiling studies, including by our group in 2009, consistently observed a significantly lower frequency of EGFR mutation in AA vs. White NSCLC, whereas three recent reports appear to directly contradict these findings. Reasons for this discrepancy are unclear, but one plausible explanation arises from Simpson's paradox, the consequence of aggregating heterogeneous study cohorts (in this case, the proportion of never-smokers in the study cohort). Our review of all prior studies (combined total 386 AA NSCLC cases) underscores the wide variation in the proportion of AA never-smokers among various studies (13-57%), calling inter-study comparisons into question. In parallel, we assessed objective response by RECIST to EGFR targeted therapy for AA NSCLC in the community setting, prior to the advent of routine EGFR testing. We observed a trend toward reduced response for community-based treatment of unselected AA NSCLC (5%; 3/57) as compared to overall response rates of 10% reported by large North American trials of primarily White NSCLC patients, but this was not significant (P=0.223).

KW - African-American

KW - Epidermal growth factor receptor (EGFR)

KW - Non-small cell lung cancer

KW - Simpson's paradox

UR - http://www.scopus.com/inward/record.url?scp=84942514507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942514507&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2218-6751.2013.01.04

DO - 10.3978/j.issn.2218-6751.2013.01.04

M3 - Review article

VL - 2

SP - 251

EP - 255

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 3

ER -